1e
19
1
49
2
2
18
1b
1d
18
47
86
1d
2 29
1d
25
Michael Miller, MD, FACC,FAHA,FNLA, FASPC
78
86
Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania
28
79
3
5f
Vice Chair of Medicine, Hospital of the University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
65
4
3
3
3
2
29
4
b
1f
65
Michael J. Crescenz Veteran’s Affairs Medical Center
37 3900 Woodland Avenue
Philadelphia, PA 19104
26
37 3900 Woodland Avenue
Philadelphia, PA 19104
2e
Office: 410-905-5584
30
ab
12
30
13
Education:
21 7 BA 23 (Biobehavioral Sciences) c
28 Rutgers College, 1979.
21 7 MD 1f (Degree of Medicine) c
3a Rutgers University Medical School, 1983.
c
3
3
3
3
8d
Permanent link21 7 BA 23 (Biobehavioral Sciences) c
28 Rutgers College, 1979.
21 7 MD 1f (Degree of Medicine) c
3a Rutgers University Medical School, 1983.
c
2 29
21
1e
1d
24
2b
29
27
23
184 Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN: Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. J Clin Lipidol 2024.
141 Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S: Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. Cardiology 2024.
18c Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. : Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2024.
156 Szarek M, Bhatt DL, Miller M, Brinton E, Jacobson TA, Tardif J-C, Ballantyne CM, Mason RP, Ketchum SB. Pineda AL, Doyle RT, Steg PG, REDUCE-IT Investigators. : Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol 2024.
15d Alfaro G, Pendyala J, Sulewski M, Miller M, Vitali C, Cuchel M. : Longitudinal analysis of clinical and laboratory biomarkers in a patient with Familial Lecithin: Cholesterol acyltransferase deficiency (FLD) and accelerated eGFR decline: a case study. . J Clin Lipidol 2024.
12a Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG.: Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024.
182 Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P: Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc 13, 2024.
d8 Miller M: Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol 2024.
17b Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM. : Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Eur Heart J Open 3(6), November 2023.
2c
7
1d
1f
Selected Publications
15a Zisman E, Hossain M, Funderburg NT, Christenson R, Jeudy J, Burrowes S, Hays AG, George N, Freeman ML, Rebuck H, Mitchell SE, Miller M, Bagchi S.: Association of Lipoprotein (a) with peri-coronary inflammation in persons with and without HIV infection. J Clin Lipidol 2024.184 Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN: Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. J Clin Lipidol 2024.
141 Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S: Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. Cardiology 2024.
18c Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. : Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2024.
156 Szarek M, Bhatt DL, Miller M, Brinton E, Jacobson TA, Tardif J-C, Ballantyne CM, Mason RP, Ketchum SB. Pineda AL, Doyle RT, Steg PG, REDUCE-IT Investigators. : Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol 2024.
15d Alfaro G, Pendyala J, Sulewski M, Miller M, Vitali C, Cuchel M. : Longitudinal analysis of clinical and laboratory biomarkers in a patient with Familial Lecithin: Cholesterol acyltransferase deficiency (FLD) and accelerated eGFR decline: a case study. . J Clin Lipidol 2024.
12a Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG.: Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024.
182 Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P: Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc 13, 2024.
d8 Miller M: Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol 2024.
17b Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM. : Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Eur Heart J Open 3(6), November 2023.
2c